Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study

Authors

M. A. Riedl, University of California - San Diego
H. J. Wedner, Washington University School of Medicine in St. Louis
et al

Journal

Allergy

Publication Date

2018

Volume

73

Issue

9

First Page

1871

Last Page

1880

Document Type

Open Access Publication

DOI

10.1111/all.13466

Rights and Permissions

Riedl, MA, Aygören‐Pürsün, E, Baker, J, et al. Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS‐2 study. Allergy. 2018; 73: 1871– 1880. https://doi.org/10.1111/all.13466 © 2018 The Authors. Allergy Published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

Recommended Citation

Riedl, M. A.; Wedner, H. J.; and et al, "Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study." Allergy. 73, 9. 1871 - 1880. (2018).
https://digitalcommons.wustl.edu/open_access_pubs/8287